ERC Advanced Grant · 2024
Today cancer remains a huge health concern, with around 20 million new cases and 10 million deaths per year worldwide. However, according to expectations, Nanomedicine should have ended cancer long time ago. The first nanomedicine (DoxilTM) a liposomal formulation based on the Enhanced Permeation and Retention (EPR) effect, dates from 1995. In the ensuing three decades, hundreds of anticancer nanoparticles with exciting properties were developed, but only a handful have reached the clinic, with rather limited effectiveness. Recent research has identified the root causes of the failure of Nanomedicine in cancer, which can be narrowed down to two problems: first, most nanoparticles (NPs) end…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.